B-Roll Advisory - Health Canada Approves Once-Daily Januvia, the First Treatment in a New Class of Medicines for Type 2 Diabetes

TORONTO, Jan. 3 /CNW/ - Merck Frosst Canada Ltd. announced today that JANUVIA(TM) has been approved by Health Canada. JANUVIA(TM) (sitagliptin phosphate monohydrate), is the first of a new class of oral diabetes medications called DPP-4 inhibitors, which enhances the body's own ability to lower blood sugar, but is not associated with weight gain or hypoglycemia (very low blood sugar). JANUVIA(TM) will help answer an unmet need in diabetes treatment.